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Background: The herbal preparation DAS-77, used for the treatment of various ailments in Nigeria, contains the
milled bark of Mangifera indica L. and root of Carica papaya L. Toxicological assessment of the preparation was
carried out in this study.
Methods: In the acute toxicity study, DAS-77 was administered to mice p.o. up to 20 g/kg in divided doses and i.p.
at 250–3000 mg/kg. Mortality within 24 h was recorded. In the chronic toxicity study, rats were treated p.o. for
90 days at doses of 80, 400 (therapeutic dose, TD) and 2000 mg/kg. By 90 days, animals were sacrificed and blood
samples collected for hematological and biochemical analysis. Organs were harvested for weight determination,
antioxidants and histopathological assessments.
Results: DAS-77 did not produce any lethality administered p.o. up to 20 g/kg in divided doses but the i.p. LD50
was 1122.0 mg/kg. At TD, DAS-77 produced significant (p< 0.05) reductions in body weight, food intake and K+,
and increases in ovary weight, neutrophils and HDL, which were reversible. Histopathological presentations were
generally normal. Effects at the other doses were comparable to those at TD except for reversible increases in
antioxidants in the liver, kidney and testes, and sperm abnormality, and reductions in liver enzymes, sperm motility
and count.
Conclusions: Findings in this study revealed that DAS-77 is relatively safe with the potential for enhancing in vivo
antioxidant activity. However, possibly reversible side-effects include electrolyte imbalance and sterility in males.
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Herbal medicines as preparations derived from naturally
occurring plants with medicinal or preventive properties
are a major component in all indigenous peoples’ trad-
itional medicine, including Ayurvedic, homeopathic, na-
turopathic, traditional oriental, Native American [1] and
African medicine. Aside from the discovery of numerous
orthodox drugs from the study of traditional cures and
folk knowledge, the efficacy of a number of botanicals
has been proven scientifically. Based on a number of fac-
tors like cultural significance, accessibility, affordability
and perceived safety, herbal medicines remain relevant
in the primary health care of indigenous populations* Correspondence: ooadey@yahoo.com
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reproduction in any medium, provided the orworldwide. The World Health Organization (WHO)
estimates that 4 billion people, about 80% of the world’s
population, use herbal medicines for some aspect of pri-
mary health care [1]. It is estimated that 70% of indigen-
ous populations in developing countries rely on
phytotherapy [2] and 25% of drugs in typical western
pharmacies are plant-derived [3]. In view of their avail-
ability for sale at a wide range of retail outlets, the extent
of their advertisement in the popular media, and the en-
trance of several major pharmaceutical companies into
the business of producing phytomedicinal products, phy-
tomedicines have clearly re-emerged into the main-
stream as a point of call in primary health care [4–6].
Considering the challenges confronting the appropri-
ate delivery of official health care to millions of people
in remote and rural communities which serve as abode
for over 70% of the population, including socio-Ltd. This is an Open Access article distributed under the terms of the Creative
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plies, prevalent transportation difficulties, shortage of
needed expertise for rational use of drugs, shortage and
cost of orthodox products [2], the most viable way to
bridge the gap in medicare is herbal medicines. The real-
ities on ground pose challenges to scientists and govern-
ments of developing countries with respect to the
development and production of standardized herbal
medicines. WHO has advocated for the proper identifi-
cation, sensible exploitation, scientific development and
appropriate utilization of herbal medicines which pro-
vide safe and effective remedies in medicare [2]. Herbal
remedies are generally regarded as safe and are pro-
moted to the public as being “natural” and completely
“safe” [7], owing to long history of use [8]. The surge in
popularity and patronage of herbal medicines necessitate
concern based on adverse effects of potentially toxic
constituents in plants (e.g. aristolochic acids, pyrrolizi-
dine alkaloids, benzophenanthrine alkaloids, lectins, vis-
cotoxins, saponins, diterpenes, cyanogenetic glycosides
and furonocoumarins) which can be fatal [9]. Pharmaco-
logical and toxicological evaluations of medicinal plants
are essential for drug development [10–12]. So much
has been done in screening herbal medicines for efficacy
based on traditional claims while less emphasis is placed
on the issue of safety, as reports of efficacy far outnum-
ber those of toxicity. For example, of 112 abstracts
accepted for presentation at the 2011 conference of the
West African Society for Pharmacology (WASP) held at
the Kwame Nkrumah University of Science and Tech-
nology (KNUST), Kumasi, Ghana, 70 (62.5%) were on
herbal medicines while 42 (37.5%) were on other aspects
of Pharmacology. Of the 70 on herbal medicines, 56
(80%) attested to efficacy while 14 (20%) raised issues of
safety with 8 being on both efficacy and safety. The sum-
mary is that presentations attesting to beneficial effects
of herbal remedies were four times those cautioning
about their safety (personal communication by the Presi-
dent of WASP, Prof. Helen Kwanashie).
DAS-77 is a herbal preparation that contains the milled
dried callous bark of mango (Mangifera indica Linn., Ana-
cardiaceae) and the dried root of pawpaw (Carica papaya
Linn., Caricaceae). It is used to treat diverse ailments in
Nigeria including ulcers, diarrhea, sexually transmitted
infections, dysmenorrhea, cholera, stomach disorders, dys-
entery and hemorrhoids. Due to multiplicity of usage and
tendency for prolonged use, the herbal preparation was
investigated in this study for possible chronic toxicity
effects using a 90 day administration schedule.
Methods
Herbal product
The herbal preparation DAS-77 is a product of Doynik
Ventures, Ijoko-Lemode, via Sango Ota, Ogun State,Nigeria. It contains the milled young callous bark of
mango (Mangifera indica) and the dried root extract of
pawpaw (Carica papaya) (1:1). The product is a light
brown, coarse powder with a pungent smell, and solu-
tion pH 8.5. DAS-77 was constituted in distilled water
before administration to experimental animals.
Experimental animals
Inbred Wistar rats and mice of both sexes, averagely
weighing 200 g and 15 g respectively, used in this study
were obtained from the Laboratory Animal Center of
the College of Medicine, University of Lagos, Lagos,
Nigeria. The animals were maintained under standard
environmental conditions (23-25°C, 12 h/12 h light/dark
cycle) and had free access to standard rodent pellet diet
(Livestock Feeds PLC, Ikeja, Lagos State, Nigeria) and
water ad libitum. The protocol used in this study was
approved by the Experimentation Ethics Committee on
Animal Use of the College of Medicine, University of
Lagos, Lagos, Nigeria, and it was in accordance with the
United States National Institutes of Health Guidelines
for Care and Use of Laboratory Animals in Biomedical
Research [13].
Phytochemical screening
Preliminary phytochemical screening (qualitative and
quantitative) of DAS-77 was done according to the
methods of Harborne [14], Trease and Evans [15] and
Edeoga et al. [16].
Acute toxicity study
Mice were generally fasted for 12 h prior to the com-
mencement of this test. A group of animals received
DAS-77 orally (p.o.) at a dose of 20 g/kg in divided
doses. Six other groups of mice (n = 5) separately
received distilled water 10 ml/kg and DAS-77 at doses
of 250, 500, 1000, 2000, and 3000 mg/kg intraperitone-
ally (i.p.). Mice were generally observed for toxic symp-
toms and behavioural changes (sedation, hyperactivity,
diarrhea, writhing, piloerection, restlessness etc.) for 2 h
post-administration. The median lethal dose (LD50) was
estimated by the log dose-probit analysis method [17,18]
based on mortality recorded within 24 h.
Chronic toxicity study
A total of 80 rats were randomly allotted to 4 groups of
14 male and 6 female animals each housed separately in
polypropylene cages. The animals were daily treated p.o.
with distilled water (control) and DAS-77 at doses of 80,
400, and 2000 mg/kg (representing one-fifth of the
pharmacologically active dose, the pharmacologically ac-
tive dose, and five times the pharmacologically active
dose respectively [19,20] for 90 days. The pharmaco-
logically active dose was the most effective dose in the
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DAS-77 in our laboratory (unpublished data).
Rats were weighed weekly and observed for behavioral
changes, feeding and drinking habits, and general mor-
phological changes. At the end of the 90 day treatment
period, 10 rats from each group were anaesthetized by
i.p. administration of 5 ml/kg of a solution of 1% chlora-
lose in 25% urethane (w/v) [8]. Blood samples were col-
lected from rats by cardiac puncture into EDTA
(ethylenediamine-tetra acetate) sample bottles for
hematological analysis and into plain sample bottles for
serum generation for biochemical analysis. Serum was
obtained after allowing blood to coagulate for 30 min.
and centrifugation. Semen was obtained from male rats
for assessment of sperm motility, count and morphology
according to the method of Cheesbrough [21]. After sac-
rificing the experimental animals, vital organs including
the heart, lungs, spleen, kidneys, lungs, testicles, ovaries,
epididymis and pancreas were harvested, carefully exam-
ined for gross lesions, and weighed. The weight of each
organ was standardized to 100 g body weight of each ani-
mal. Samples were taken from each of the organs for de-
termination of in vivo antioxidants and malondialdehyde
(MDA). The remnants of the organs were preserved in
10% formol-saline for histopathological assessment.
Mortality in each treatment group was recorded dur-
ing the course of the 90 day administration of DAS-77
and reversibility period of 30 days in which animals were
not treated with the herbal preparation. At the end of
the reversibility period, rats were sacrificed and assays
conducted in the main study were done.
Hematological analysis
Blood samples were analyzed using established proce-
dures and automated hematology analyzer. Parameters
evaluated include packed cell volume (PCV), red blood
cell (RBC) count, hemoglobin (Hb), platelet count, total
and differential white blood cell (WBC) count, mean cell
hemoglobin concentration (MCHC), mean red cell vol-
ume (MCV), and mean cell hemoglobin (MCH).
Biochemical analysis
Serum samples were analyzed for creatinine, urea, albu-
min, total protein, cholesterol, high density lipoprotein
(HDL), low density lipoprotein (LDL), triglycerides (TG),
glucose, uric acid, alkaline phosphatase (ALP), aspartate
transaminase (AST), alanine transaminase (ALT), total
bilirubin, and direct bilirubin using Roche and Cobas com-
mercial kits and Roche/Hitachi 904 automated analyzer.
Serum electrolytes concentration was determined by
established methods; sodium and potassium concentration
by flame photometry, chloride and bicarbonate concentra-
tion by titrimetric method, and calcium concentration by
cresol phthalein complexone method [22–24].Sperm analysis
Sperm analysis to assess seminal fluid for motility, count
and morphology was carried out according to the
methods of Cheesbrough [21] and Ogli et al. [25]. Male
rats were sacrificed and strapped astride on their back
on dissecting board. The testis was removed with its ip-
silateral epididymis into a beaker after incision on the
right scrotum. Subsequently, semen was expelled out
of the epididymis into a beaker placed in water bath at
36°C [25].
Sperm motility
Semen (10–15 μl) was placed on a slide in a way that
the spermatozoa were evenly distributed and covered
with a glass. After appropriate focus, several fields of the
specimen were assessed for motility using the 40 × ob-
jective of the microscope. The number of motile cells
was noted out of a total of 100 spermatozoa.
Sperm count
Using sodium bicarbonate-formalin diluting fluid, a 1 in
20 dilution of semen was carried out with thorough mix-
ing. An improved Neubauer ruled chamber was filled
with well-mixed diluted semen using a Pasteur pipette.
The number of spermatozoa in an area of 2 sq mm was
counted using the 10 × objective of the microscope after
3–5 min. Estimation of the number of spermatozoa in
1 ml of fluid was done by multiplication of the number
counted by 100 000.
Sperm morphology
A thin smear of the liquefied well-mixed semen, made
on a slide, was fixed with 95% v/v ethanol while still wet
for 5–10 min. This was allowed to air-dry after which it
was washed with sodium bicarbonate-formalin solution.
This was to remove any present mucus. Rinsing with
water was carried out many times. Subsequently, the
smear was covered with dilute carbon fuchsin (1 in 20).
This was allowed to stain for 3 min and the stain was
washed off with water. Dilute Loeffler’s methylene blue
(1 in 20) was used to cover the smear for 2 min to
achieve counterstaining. This was washed off with water,
drained and allowed to dry. Normal and abnormal
spermatozoa were examined using the 40 × objective of
the microscope. Estimation of percentage normal and
abnormal morphology was done from the counting of
hundred spermatozoa.
Measurement of in vivo antioxidants and
malondialdehyde (MDA) levels
Reduced glutathione (GSH), superoxide dismutase
(SOD), catalase (CAT), glutathione peroxidase (GPx),
and MDA were determined according to established
































Figure 1 Effect of DAS-77 on body weight of male rats. Values
are presented as mean± SEM (n= 7). ap< 0.05, bp< 0.01, cp< 0.001
vs. control (One-way ANOVA followed by Dunnet’s posttest).






























Figure 3 Effect of DAS-77 on daily food intake. Values are
presented as mean± SEM (n = 7). ap< 0.05, bp< 0.01, cp< 0.001 vs.
control (One-way ANOVA followed by Bonferroni posttests).
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determination of total protein [30].Histopathological assessment
The various tissues obtained from experimental animals
fixed in 10% formol-saline were dehydrated in graded al-
cohol, embedded in paraffin, and cut into 4–5 μm thick
sections. Hematoxylin-eosin was used to stain the sec-
tions for photomicroscopic assessment using a Model
N-400ME photomicroscope (CEL-TECH Diagnostics,
Hamburg, Germany) [31,32]. Slides were examined using
the × 40, × 100, and × 400 objectives.Statistical analysis
Results are expressed as mean ± SEM. Data analysis was
carried out using One-way ANOVA followed by
Dunnet’s and Bonferroni posttests using GraphPad
Prism 5 (GraphPad Software Inc., CA, USA). Signifi-
cance was considered at values of p < 0.05.)Results
Phytochemical screening
Preliminary phytochemical screening of DAS-77 showed
the presence of tannins (3.26%), saponins (2.32%),
phenols (1.31%), flavonoids (0.54%) and alkaloids
(0.04%). Percentages represent the crude yield of the

































Figure 2 Effect of DAS-77 on body weight of female rats. Values
are presented as mean± SEM (n = 3). ap< 0.05, bp< 0.01, cp< 0.001
vs. control (One-way ANOVA followed by Dunnet’s posttest).Acute toxicity
No mortality and visible signs of toxicity were observed
upon administration of DAS-77 p.o. up to 20 g/kg in
divided doses. Administered i.p., mortality was 0% at the
lowest dose of 250 mg/kg and 100% at the highest dose
of 3000 mg/kg, with the LD50 graphically estimated to
be 1122.0 mg/kg. Writhing, grooming, increased loco-
motor activity, and convulsion were the behavioral man-
ifestations observed with the i.p. route.
Effect of DAS-77 on body weight, food and water intake
In respect of male rats, compared to control, DAS-77 at
the dose of 80 mg/kg caused significant reduction
(p < 0.01, 0.001) in change in body weight on days 63
and 70. The same trend of effect was obtained with
DAS-77 at doses of 400 mg/kg (p < 0.05) and 2000 mg/
kg (p < 0.001) but on days 42 and 90, and 84 and 90 re-
spectively (Figure 1).
Concerning female rats, compared to control, DAS-77
at the dose of 80 mg/kg caused significant increase
(p < 0.05, 0.01) in change in body weight on days 84 and
90. At the dose of 400 mg/kg, the herbal remedy elicited
significant reduction (p < 0.01, 0.001) on days 28 and 56.
DAS-77 at the dose of 2000 mg/kg did not produce any
significant effect on change in body weight all through
































Figure 4 Effect of DAS-77 on daily water intake. Values are
presented as mean± SEM (n = 7). cp< 0.001 vs. control (One-way
ANOVA followed by Bonferroni posttests).
Table 1 Effect of DAS-77 on animal weight, food and water intake
Treatment Dose (mg/kg) Weight change (g) Food intake (g) Water intake (ml)
Distilled water (10 ml/kg) 10.46 ± 0.97 289.80± 4.46 519.10 ± 22.73
DAS-77 80 7.23 ± 1.13 276.40± 3.03 529.20 ± 13.91
DAS-77 400 3.85 ± 1.61** 268.40± 3.21** 519.00 ± 12.13
DAS-77 2000 5.85 ± 1.74 254.60± 6.64*** 517.70 ± 11.86
Values are mean ± S.E.M (n = 10). **p< 0.01, ***p< 0.001 vs. distilled water (One-way ANOVA followed by Dunnett’s posttest).
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effect (p < 0.05, 0.01, 0.001) on average daily food intake
at the dose of 2000 mg/kg only. At this dose, there were
reductions in average daily food intake on days 14, 21,
42 and 84 compared to control (Figure 3).
Concerning water intake, DAS-77 at the dose of
400 mg/kg caused significant increase (p < 0.001) in aver-
age daily water intake on day 21 compared to control.
The herbal remedy at doses of 80 and 2000 mg/kg did
not elicit any significant effect all through the treatment
period (Figure 4).
In general, considering the 90 day end-point, DAS-77
at the dose of 400 mg/kg produced a significant reduc-
tion (p < 0.01) in weight change (3.85 ± 1.61 g) compared
to control (10.46 ± 0.97 g) while effects were not signifi-
cant at 80 and 2000 mg/kg. The herbal preparation also
elicited a significant reduction (p < 0.01, 0.001) in food
intake at doses of 400 and 2000 mg/kg (268.40 ± 3.21
and 254.60 ± 6.64 g, respectively) relative to control
(289.80 ± 4.46 g). DAS-77 did not produce any signifi-
cant effect on water intake (Table 1).
Effect of DAS-77 on sperm motility, sperm count, and
morphology (% abnormality)
At doses of 80 and 400 mg/kg, DAS-77 did not produce
any significant effect on sperm motility, count, and ab-
normality. However at the dose of 2000 mg/kg,
the herbal preparation significantly reduced (p < 0.05,
0.01) sperm motility (42.71 ± 10.33% vs. control value
of 85.00 ± 6.00%) and sperm count (14.71 ± 3.00 million/
ml vs. control value of 31.14 ± 2.50 million/ml), and
increased sperm abnormality (12.43 ± 2.26% vs. control
value of 5.14 ± 1.10%). These effects were reversed










Distilled water (10 ml/kg) 85.00 ± 6.00 31.14 ± 2.50 5
DAS-77 80 73.43 ± 12.61 25.57 ± 4.07 8
DAS-77 400 87.29 ± 12.05 33.00 ± 3.52 4
DAS-77 2000 42.71 ± 10.33* 14.71 ± 3.00** 12
Values are mean ± S.E.M (n = 7, main study; n = 5, reversibility study). *p< 0.05, **p<Effect on weight of vital organs (per 100 g body weight)
DAS-77 did not produce any significant effect on the
weight of vital organs except in the case of the liver in
which there was a significant reduction (p < 0.05) in
weight (2.41 ± 0.10 g vs. 2.84 ± 0.05 g for control) at the
dose of 2000 mg/kg and the ovaries in which there were
significant increases (p < 0.01) in weight (0.14 ± 0.02 g
and 0.14 ± 0.01 g respectively vs. 0.08 ± 0.00 g for con-
trol) at doses of 400 and 2000 mg/kg (Table 3). The
effects produced in the liver and ovaries were reversed
upon cessation of treatment for 30 days (Table 4). DAS-
77 did not produce any significant effect on the weight
of the lungs in the main study but at the dose of
400 mg/kg a significant increase (p < 0.05) was observed
in the reversibility study (0.88 ± 0.03 g vs. 0.73 ± 0.06 g
for control).Effect of DAS-77 on hematological parameters
DAS-77 did not produce any significant effect on
hematological parameters after the 90 day administra-
tion except in respect of WBC count in which there was
a significant decrease (p < 0.05) in the group treated with
the herbal preparation at the dose of 2000 mg/kg
(5.20 ± 0.58 × 10³/μl) when compared with the group
treated with distilled water (9.40 ± 0.98 × 10³/μl) (Table 5).
There was also a significant increase (p < 0.05, 0.01) in
the proportion of neutrophils in the groups treated with
DAS-77 at doses of 80 mg/kg (46.10 ± 2.16%), 400 mg/
kg (56.30 ± 1.54%) and 2000 mg/kg (60.90 ± 1.38%) com-
pared to control (39.80 ± 1.95%). The effects of DAS-77
on WBC count and proportion of neutrophils were
reversed after 30 days of cessation of administration










.14 ± 1.10 81.60 ± 7.17 25.80 ± 4.28 7.20 ± 1.72
.86 ± 2.42 72.33 ± 9.30 24.67 ± 3.53 8.33 ± 2.01
.14 ± 1.44 70.80 ± 9.07 23.00 ± 2.54 7.40 ± 1.50
.43 ± 2.26* 74.25 ± 13.56 25.50 ± 5.52 5.50 ± 1.71
0.01 vs. distilled water (One-way ANOVA followed by Dunnett’s posttest).
Table 3 Effect of DAS-77 on weight of vital organs (per 100 g body weight) in the main study
Treatment Dose (mg/kg) Main Study
Liver Kidney Lungs Heart Testes Spleen Pancreas Brain Ovaries
Distilled water (10 ml/kg) 2.84 ± 0.05 0.57 ± 0.02 0.77 ± 0.04 0.37 ± 0.03 1.52 ± 0.08 0.37 ± 0.03 0.28 ± 0.02 0.63 ± 0.03 0.08 ± 0.00
DAS-77 80 2.80 ± 0.19 0.64 ± 0.04 0.78 ± 0.05 0.34 ± 0.02 1.78 ± 0.29 0.32 ± 0.04 0.34 ± 0.03 0.70 ± 0.02 0.10 ± 0.00
DAS-77 400 2.66 ± 0.09 0.71 ± 0.03 0.88 ± 0.04 0.33 ± 0.02 1.99 ± 0.08 0.31 ± 0.02 0.42 ± 0.02 0.74 ± 0.08 0.14 ± 0.02**
DAS-77 2000 2.41 ± 0.1* 0.65 ± 0.06 0.78 ± 0.07 0.35 ± 0.02 1.91 ± 0.13 0.30 ± 0.02 0.32 ± 0.03 0.73 ± 0.01 0.14 ± 0.01*
Values are mean ± S.E.M (n = 10). *p< 0.05, **p< 0.01 vs. distilled water (One-way ANOVA followed by Dunnett’s posttest).
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There was a significant increase (p < 0.05) in the concen-
tration of albumin in the group treated with the herbal
preparation at the dose of 80 mg/kg (37.30 ± 0.78 g/L)
when compared with the group treated with distilled
water (33.20 ± 1.03 g/L) (Table 7). There was also a sig-
nificant increase (p < 0.05) in the concentration of HDL
in the groups treated with DAS-77 at doses of 80 mg/kg
(1.15 ± 0.05 mmol/L) and 400 mg/kg (1.11 ± 0.10 mmol/
L) when compared with the group treated with distilled
water (0.87 ± 0.05 mmol/L). The concentrations of AST
and ALT were significantly reduced (p < 0.001) in the
groups treated with the formulation at the dose of
2000 mg/kg (74.50 ± 8.61 u/L and 18.00 ± 2.12 u/L re-
spectively) when compared with the group treated with
distilled water (143.70 ± 11.34 u/L and 36.20 ± 4.56 u/L
respectively). The effects on albumin, HDL, AST, and
ALT were reversed after 30 days of cessation of adminis-
tration of DAS-77 (Table 8).
Effect of DAS-77 on serum electrolyte
There was a significant decrease (p < 0.05, 0.001) in the
concentration of K+ in the groups treated with the for-
mulation at the doses of 80 mg/kg (5.98 ± 0.25 mmol/L),
400 mg/kg (5.04 ± 0.10 mmol/L), and 2000 mg/kg
(5.19 ± 0.14 mmol/L) when compared with the group
treated with distilled water (7.52 ± 0.47 mmol/L)
(Table 9). There was also a significant increase (p < 0.05)
in the concentration of Ca2+ in the group treated with
DAS-77 at the dose of 2000 mg/kg (1.25 ± 0.04 mg/dL)
when compared with the distilled water treated group
(1.09 ± 0.05 mg/dL). These effects were reversed after
30 days of cessation of administration of DAS-77
(Table 10).Table 4 Effect of DAS-77 on weight of vital organs (per 100 g
Treatment Dose (mg/kg) Reversibility study
Liver Kidney Lungs He
Distilled water (10 ml/kg) 2.60 ± 0.11 0.57 ± 0.01 0.73 ± 0.06 0.3
DAS-77 80 2.53 ± 0.12 0.55 ± 0.03 0.68 ± 0.03 0.3
DAS-77 400 2.74 ± 0.12 0.62 ± 0.01 0.88 ± 0.0* 0.4
DAS-77 2000 2.79 ± 0.10 0.63 ± 0.05 0.83 ± 0.02 0.3
Values are mean ± S.E.M (n = 10). *p< 0.05 vs. distilled water (One-way ANOVA followEffect of DAS-77 on antioxidant enzymes in rat liver,
kidney, brain and testes
There was no significant difference in the levels of the
various antioxidant enzymes and MDA in the liver
(Table 11) and brain (Table 12) but in the kidney, there
was a significant increase (p < 0.05, 0.01) in the level of
catalase in the groups treated with the formulation at
doses of 80 mg/kg (58.21 ± 13.80 u/mg) and 2000 mg/kg
(44.41 ± 4.75 u/mg) compared with the distilled water
treated group (17.66 ± 5.22 u/mg) (Table 13). There
was also a significant decrease (p < 0.05, 0.01) in the
level of MDA in the groups treated with DAS-77 at
doses of 80 mg/kg (0.11 ± 0.03 nm/mg), 400 mg/kg
(0.07 ± 0.02 nm/mg), and 2000 mg/kg (0.13 ± 0.03 nm/
mg) compared with the group treated with distilled
water (0.27 ± 0.08 nm/mg). The effects on catalase and
MDA in the kidney were reversed upon discontinuation
of treatment for 30 days (Table 14).
There were significant differences in the level of anti-
oxidant enzymes in the liver across the treatment
groups after a 30 day cessation of therapy (Table 15).
At the dose of 80 mg/kg, there were significant
increases (p < 0.05, 0.01, 0.001) in the levels of GSH
(3.69 ± 0.55 vs. 1.45 ± 0.22 nm/mg in control), SOD
(5.82 ± 0.72 vs. 3.24 ± 0.33 u/mg in control), catalase
(26.87 ± 3.33 vs. 14.94 ± 1.54 u/mg in control), and per-
oxidase (1.83 ± 0.23 vs. 0.10 ± 0.10 u/mg in control).
There was no significant difference in the levels of the
various antioxidant enzymes and MDA in the brain in
the reversibility study (Table 16).
In respect of the testes and DAS-77 treatment dose of
80 mg/kg, there were significant increases (p < 0.01) in
the levels of GSH (3.58 ± 0.75 nm/mg), SOD (5.75 ± 0.82
u/mg), catalase (26.55 ± 3.79 u/mg), and peroxidasebody weight) in the reversibility study
art Testes Spleen Pancreas Brain Ovaries
6 ± 0.02 1.39 ± 0.13 0.29 ± 0.01 0.25 ± 0.03 0.78 ± 0.03 0.12 ± 0.00
5 ± 0.02 1.21 ± 0.05 0.25 ± 0.01 0.24 ± 0.02 0.82 ± 0.04 0.10 ± 0.01
2 ± 0.03 0.95 ± 0.27 0.25 ± 0.01 0.26 ± 0.02 0.71 ± 0.04 0.12 ± 0.01
8 ± 0.03 1.35 ± 0.28 0.27 ± 0.02 0.34 ± 0.02 0.82 ± 0.04 0.14 ± 0.01
ed by Dunnett’s posttest).




PCV (%) WBC (10³/μl) N (%) L (%) E (%) RBC (106/μl) PLT (104/μl) Hb (g/dl) MCV (fl) MCH (pg) MCHC (g/dl)
Distilled water (10 ml/kg) 42.90 ± 1.49 9.40 ± 0.98 39.80 ± 1.95 59.60 ± 2.04 1.50 ± 0.29 5.24 ± 0.35 34.15 ± 2.43 13.91 ± 0.47 83.30 ± 2.68 27.10 ± 0.89 32.42 ± 0.13
DAS-77 80 45.30 ± 1.37 8.84 ± 0.76 46.10 ± 2.16* 52.40 ± 1.93 2.75 ± 1.11 6.26 ± 0.50 31.90 ± 3.07 14.73 ± 0.44 75.00 ± 4.56 24.03 ±1.66 32.54 ± 0.05
DAS-77 400 42.90 ± 1.55 5.92 ± 1.60 56.30 ± 1.54** 56.30 ± 1.54 1.67 ± 0.67 4.57 ± 0.32 34.80 ± 1.92 13.93 ± 0.48 84.40 ±2.08 27.38 ± 0.72 32.50 ± 0.06
DAS-77 2000 40.60 ± 0.88 5.20 ± 0.58* 60.90 ± 1.38** 60.90 ± 1.38 3.50 ± 0.50 4.67 ± 0.12 36.04 ± 1.47 12.23 ± 1.00 87.20 ± 1.23 28.39 ± 0.41 32.60 ± 0.03
























Table 6 Effect of DAS-77 on hematological parameters in rats in the reversibility study
Treatment Dose (mg/kg) Reversibility study
PCV (%) WBC (10³/μl) N (%) L (%) E (%) RBC (106/μl) PLT (104/μl) Hb (g/dl) MCV (fl) MCH (pg) MCHC (g/dl)
Distilled water (10 ml/kg) 45.13 ± 1.16 6.91 ± 0.62 47.75 ± 3.06 51.88 ± 3.19 1.50 ± 0.05 6.93 ± 0.37 2.69 ± 0.22 14.73 ± 0.37 66.00 ± 2.30 21.53 ± 0.77 32.66 ± 0.03
DAS-77 80 43.78 ± 1.01 5.18 ± 0.78 45.00 ± 1.88 53.44 ± 2.04 2.25 ± 0.95 6.59 ± 0.27 3.74 ± 0.13 14.28 ± 0.32 66.78 ± 1.53 21.83 ± 0.52 32.61 ± 0.07
DAS-77 400 43.13 ± 1.17 6.39 ± 0.67 48.75 ± 2.26 50.13 ± 2.25 2.25 ± 0.48 6.28 ± 0.44 3.08 ± 0.14 14.10 ± 0.39 70.63 ± 3.99 23.08 ± 1.30 32.17 ± 0.04
DAS-77 2000 45.50 ± 0.96 5.12 ± 0.49 50.00 ± 2.79 49.83 ± 2.81 1.00 ± 0.00 6.92 ± 0.24 3.93 ± 0.24 14.83 ± 0.31 66.17 ± 1.01 21.48 ± 0.35 32.60 ± 0.04































































63.40±1.06 8.69±0.29 33.20±1.03 72.50±1.85 1.80±0.16 0.87 ± 0.05 0.65 ± 0.18 0.61±0.06 1.64±0.29 104.20 ±23.85 40.40±4.89 143.70 ± 11.34 36.20±4.56 5.70 ± 0.26 1.40±0.31
DAS-77 80 54.80±3.46 9.51 ± 0.40 37.30±0.78* 75.80±0.98 1.91 ±0.11 1.15 ± 0.05* 0.59 ± 0.13 0.41± 0.05 1.60 ± 0.16 75.33 ± 9.17 33.07 ±3.47 111.20±14.8 31.80±2.05 5.40±0.22 1.10±0.1
DAS-77 400 55.50±3.21 9.93 ± 0.62 35.20± 1.59 74.10±3.26 1.72±0.15 1.11 ± 0.10* 0.43 ± 0.08 0.41±0.07 1.58 ± 0.23 60.18 ± 5.66 34.02±3.15 80.0 ± 6.21 18.2±1.26 5.80 ±0.25 1.40±0.31
DAS-77 2000 57.00±2.08 9.12 ± 0.59 35.20 ±1.03 78.80±1.71 1.77±0.16 1.01 ± 0.06 0.62 ± 0.16 0.48 ±0.08 1.57 ± 0.15 58.77 ± 4.33 40.54±4.78 74.50±8.61*** 18.00±2.12*** 5.40 ±0.22 1.30±0.15




























































(10 ml/kg) 58.75±2.95 7.68±0.38 39.5±1.68 83.13±3.14 2.4± 0.25 1.59±0.15 0.50±0.18 0.65±0.10 1.93 ± 0.36 93.74 ± 8.50 28.23± 5.48 65.88±7.87 31.75±3.08 5.75±0.31 1.50± 0.27
DAS-77 80 60.11±2.67 7.72±0.36 40.89±1.35 84.11 ±3.25 2.18±0.15 1.61± 0.15 0.24±0.04 0.70± 0.08 2.36 ± 0.34 85.33 ± 5.54 20.11±2.57 58.56 ±5.26 26.67±1.62 5.22±0.15 1.44±0.18
DAS-77 400 54.50±1.05 7.41±0.52 39.00±1.60 85.38±3.69 2.25±0.33 1.61±0.32 0.70± 0.16 0.68±0.13 1.84 ± 0.28 97.75 ± 10.75 25.69 ±3.09 51.50±4.05 33.63±2.06 5.38±0.26 1.50±0.38
DAS-77 2000 55.50±2.05 7.12±0.31 38.50±1.34 84.67 ±6.04 1.90 ±0.24 1.10± 0.18 0.47±0.09 0.70± 0.10 2.03 ± 0.48 111.20±13.20 29.50 ±3.47 74.50± 11.22 35.33±4.55 5.17±0.17 1.00 ± .00
























Table 9 Effect of DAS-77 on serum electrolytes in the main study
Treatment Dose (mg/kg) Main study
Na+ (mmol/L) K+ (mmol/L) Cl− (mmol/L) HCO3
− (mmol/L) Ca2+ (mg/dl)
Distilled water (10 ml/kg) 156.60 ± 4.44 7.52 ± 0.47 100.90 ± 3.73 10.56 ± 1.45 1.09 ± 0.05
DAS-77 80 150.30 ± 0.59 5.98 ± 0.25* 105.40 ± 0.38 10.13 ± 0.58 1.05 ± 0.03
DAS-77 400 152.70 ± 3.39 5.04 ± 0.10*** 105.10 ± 0.53 12.70 ± 0.50 1.20 ± 0.03
DAS-77 2000 149.70 ± 0.90 5.19 ± 0.14*** 104.70 ± 0.90 13.20 ± 0.84 1.25 ± 0.04*
Values are mean ± S.E.M. (n = 10). *p< 0.05, ***p< 0.001 vs. distilled water (One-way ANOVA followed by Dunnett’s posttest).
Table 10 Effect of DAS-77 on serum electrolytes in the reversibility study
Treatment Dose (mg/kg) Reversibility study
Na+(mmol/L) K+ (mmol/L) Cl−(mmol/L) HCO3
− (mmol/L) Ca2+ (mg/dl)
Distilled water (10 ml/kg) 154.90 ± 1.29 5.19 ± 0.17 104.50 ± 0.93 11.38 ± 0.68 1.18 ± 0.05
DAS-77 80 154.80 ± 0.64 4.99 ± 0.17 106.70 ± 0.71 12.33 ± 0.88 1.12 ± 0.05
DAS-77 400 153.30 ± 0.80 5.09 ± 0.15 105.80 ± 1.07 11.63 ± 0.60 1.15 ± 0.04
DAS-77 2000 158.00 ± 1.07 5.10 ± 0.15 108.20 ± 1.17 11.83 ± 0.60 1.08 ± 0.05
Values are mean ± S.E.M. (n = 10). p> 0.05 vs. distilled water (One-way ANOVA followed by Dunnett’s posttest).
Table 11 Effect of DAS-77 on antioxidant enzymes in rat liver in the main study
Treatment Dose (mg/kg) Main study
GSH (nm/mg) SOD (u/mg) CAT(u/mg) Peroxidase (u/mg) MDA (nm/mg) Protein(mg)
Distilled water (10 ml/kg) 1.78 ± 0.40 4.25 ± 1.31 19.62 ± 6.04 1.27 ± 0.39 0.11 ± 0.05 52.68 ± 6.14
DAS-77 80 1.75 ± 0.17 6.65 ± 0.39 30.65 ± 1.81 2.08 ± 0.12 0.04 ± 0.00 61.64 ± 6.92
DAS-77 400 2.07 ± 0.15 5.59 ± 1.03 25.76 ± 4.74 1.75 ± 0.32 0.11 ± 0.03 43.80 ± 5.34
DAS-77 2000 2.03 ± 0.26 6.62 ± 1.05 30.49 ± 4.81 2.08 ± 0.33 0.11 ± 0.02 47.08 ± 4.04
Values are mean ± S.E.M. (n = 5). p> 0.05 vs. distilled water (One-way ANOVA followed by Dunnett’s posttest).
Table 12 Effect of DAS-77 on antioxidant enzymes in rat brain in the main study
Treatment Dose (mg/kg) Main study
GSH (nm/mg) SOD (u/mg) CAT (u/mg) Peroxidase (u/mg) MDA (nm/mg) Protein (mg)
Distilled water (10 ml/kg) 1.35 ± 0.29 3.94 ± 1.26 18.19 ± 5.80 1.24 ± 0.39 0.23 ± 0.02 30.68 ± 3.80
DAS-77 80 1.89 ± 0.32 3.13 ± 0.75 14.44 ± 3.44 0.98 ± 0.23 0.28 ± 0.11 38.27 ± 6.34
DAS-77 400 1.68 ± 0.28 1.94 ± 0.28 8.96 ± 1.30 0.61 ± 0.09 0.18 ± 0.01 29.65 ± 4.47
DAS-77 2000 1.83 ± 0.30 2.38 ± 0.52 10.93 ± 2.42 0.74 ± 0.17 0.21 ± 0.02 27.47 ± 3.10
Values are mean ± S.E.M. (n = 5). p> 0.05 vs. distilled water (One-way ANOVA followed by Dunnett’s posttest).
Table 13 Effect of DAS-77 on antioxidant enzymes in rat kidney in the main study
Treatment Dose (mg/kg) Main study
GSH (nm/mg) SOD (u/mg) CAT(u/mg) Peroxidase(u/mg) MDA (nm/mg) Protein (mg)
Distilled water (10 ml/kg) 1.69 ± 0.15 3.41 ± 0.73 17.66 ± 5.22 1.26 ± 0.34 0.27 ± 0.08 28.94 ± 5.64
DAS-77 80 2.76 ± 0.83 12.31 ± 3.01 58.21 ± 13.80** 3.96 ± 0.94 0.11 ± 0.03* 50.22 ± 10.34
DAS-77 400 2.12 ± 0.21 7.69 ± 0.53 35.46 ± 2.43 2.32 ± 0.15 0.07 ± 0.02** 51.13 ± 3.57
DAS-77 2000 2.17 ± 0.18 9.63 ± 1.03 44.41 ± 4.75* 3.02 ± 0.32 0.13 ± 0.03* 35.22 ± 2.57
Values are mean ± S.E.M. (n = 5). *p< 0.05, **p< 0.01 vs. distilled water (One-way ANOVA followed by Dunnett’s posttest).
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Table 14 Effect of DAS-77 on antioxidant enzymes in rat kidney in the reversibility study
Treatment Dose (mg/kg) Reversibility study
GSH (nm/mg) SOD (u/mg) CAT (u/mg) Peroxidase (u/mg) MDA (nm/mg) Protein (mg)
Distilled water (10 ml/kg) 2.03 ± 0.37 3.30 ± 0.45 15.24 ± 2.08 1.04 ± 0.14 0.13 ± 0.01 32.56 ± 1.70
DAS-77 80 2.22 ± 0.46 3.48 ± 0.59 16.07 ± 2.70 1.09 ± 0.18 0.15 ± 0.02 30.88 ± 4.35
DAS-77 400 1.09 ± 0.14 2.04 ± 0.18 9.43 ± 0.85 0.64 ± 0.06 0.15 ± 0.02 35.49 ± 4.60
DAS-77 2000 2.31 ± 0.42 3.05 ± 0.49 14.07 ± 2.24 0.96 ± 0.15 0.14 ± 0.02 34.32 ± 5.29
Values are mean ± S.E.M. (n = 5, main study). p> 0.05 vs. distilled water (One-way ANOVA followed by Dunnett’s posttest).
Table 15 Effect of DAS-77 on antioxidant enzymes in rat liver in the reversibility study
Treatment Dose (mg/kg) Reversibility study
GSH (nm/mg) SOD (u/mg) CAT(u/mg) Peroxidase (u/mg) MDA (nm/mg) Protein(mg)
Distilled water (10 ml/kg) 1.45 ± 0.22 3.24 ± 0.33 14.94 ± 1.54 0.10 ± 0.10 0.19 ± 0.02 34.68 ± 1.91
DAS-77 80 3.69 ± 0.55*** 5.82 ± 0.72** 26.87 ± 3.33** 1.83 ± 0.23** 0.19 ± 0.02 24.41 ± 2.52**
DAS-77 400 1.70 ± 0.31 3.62 ± 0.56 16.72 ± 2.58 1.14 ± 0.18 0.22 ± 0.01 24.35 ± 1.40*
DAS-77 2000 2.29 ± 0.15 3.71 ± 0.14 17.10 ± 0.64 1.17 ± 0.04 0.93 ± 0.81 33.10 ± 3.66
Values are mean ± S.E.M. (n = 4). *p< 0.05, **p< 0.01, ***p< 0.001 vs. distilled water (One-way ANOVA followed by Dunnett’s posttest).
Table 16 Effect of DAS-77 on antioxidant enzymes in rat brain in the reversibility study
Treatment Dose (mg/kg) Reversibility study
GSH (nm/mg) SOD (u/mg) CAT (u/mg) Peroxidase (u/mg) MDA (nm/mg) Protein (mg)
Distilled water (10 ml/kg) 3.67 ± 0.70 5.36 ± 0.91 24.72 ± 4.20 1.68 ± 0.29 0.25 ± 0.04 16.76 ± 0.94
DAS-77 80 2.49 ± 0.41 4.36 ± 0.40 20.12 ± 1.86 1.37 ± 0.13 0.28 ± 0.04 16.69 ± 1.20
DAS-77 400 2.15 ± 0.27 3.53 ± 0.33 16.29 ± 1.55 1.11 ± 0.11 0.33 ± 0.04 20.28 ± 1.22
DAS-77 2000 3.35 ± 1.20 5.26 ± 1.62 24.26 ± 7.49 1.65 ± 0.51 0.27 ± 0.04 20.76 ± 2.90
Values are mean ± S.E.M. (n = 4). p> 0.05 vs. distilled water (One-way ANOVA followed by Dunnett’s posttest).
Table 17 Effect of DAS-77 on antioxidant enzymes in rat testes
GSH (nm/mg) SOD (u/mg) CAT(u/mg) Peroxidase (u/mg) MDA (nm/mg) Protein (mg)
Distilled water (10 ml/kg) 1.12 ± 0.16 2.80 ± 0.32 13.48 ± 1.58 0.95 ± 0.12 0.26 ± 0.02 25.48 ± 1.87
DAS-77 80 3.58 ± 0.75** 5.75 ± 0.82** 26.55 ± 3.79** 1.80 ± 0.26** 0.28 ± 0.06 24.19 ± 2.22
DAS-77 400 0.65 ± 0.11 1.86 ± 0.23 8.57 ± 1.05 0.59 ± 0.07 0.19 ± 0.01 35.08 ± 2.95
DAS-77 2000 1.46 ± 0.47 2.44 ± 0.18 11.26 ± 0.85 0.77 ± 0.06 0.19 ± 0.06 38.65 ± 5.58*
Values are mean ± S.E.M. (n = 4). *p< 0.05, **p< 0.01 vs. distilled water (One-way ANOVA followed by Dunnett’s posttest).
Table 18 Histopathological presentations
Organs Distilled water(10 ml/kg) DAS-77(80 mg/kg) DAS-77(400 mg/kg) DAS-77(2000 mg/kg)
Liver Normal Normal Severe congestion Congestion
Kidney Normal Normal Normal Normal
Heart Normal Normal Normal Normal
Lungs Normal Normal Normal Normal
Brain Normal Normal Cerebral oedema Normal
Pancreas Normal Normal Normal Normal
Spleen Congestion Congestion Congestion Congestion
Ovaries Normal Normal Normal Normal
Testes Normal Normal Normal Normal
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Figure 5 Distilled water group showing the liver (normal)
(× 400).
Figure 7 DAS-77 (400 mg/kg) group showing the liver
(congested) (× 400).
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treated groups (1.12 ± 0.16 nm/mg, 2.80 ± 0.32 u/mg,
13.48 ± 1.58 u/mg, and 0.95 ± 0.12 u/mg control values,
respectively) (Table 17).Effect of DAS-77 on histopathological presentations
A summary of the histopathological presentations in the
various organs is shown in Table 18.Figure 6 DAS-77 (80 mg/kg) group showing the Liver (normal)
(× 400).Liver
There were no adverse histopathological presentations
observed in the distilled water and DAS-77 (80 mg/kg)
treatment groups. The liver appeared normal with pre-
served hepatic architecture, hepatocytes arranged as radial
plates, and having eosinophilic cytoplasm and central nu-
clei. No cytoplasmic inclusions were seen and no portal
inflammation (Figures 5 and 6). Congestion was observed
in the liver at doses of 400 and 2000 mg/kg with theFigure 8 DAS-77 (2000 mg/kg) group showing the liver
(congested) (× 400).
Figure 9 Distilled water group showing the brain (normal)
(× 400).
Figure 11 DAS-77 (400 mg/kg) group showing the brain
(cerebral oedema).
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and 8).
Kidney
There were no adverse histopathological presentations
observed in all the treatment groups. Normocellular
glomerular tufts were displayed on a background con-
taining tubules. No necrosis was observed.Figure 10 DAS-77 (80 mg/kg) group showing the brain
(normal) (× 400).Brain
Generally, there were no adverse histopathological pre-
sentations observed in the treatment groups but cerebral
oedema was observed in the 400 mg/kg group (Figures 9,
10, 11 and 12). Neuron cell bodies were displayed on a
loose fibrillary background. Prominent perineuronal and
perivascular halos or clearing (Virchow Robbins spaces)
were seen.Figure 12 DAS-77 (2000 mg/kg) group showing the brain
(normal) (× 400).
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The lungs were normal in all the treatment groups. The
alveolar air spaces were surrounded by interstitium con-
taining few blood vessels and inflammatory cells.Heart
The heart was normal in all the treatment groups. The
cardiac myocytes were arranged in interlacing and paral-
lel array. Their nuclei were spindle shaped and
elongated.Spleen
Presentations in the distilled water group were normal.
The spleen was congested in all the DAS-77 treatment
groups with the background splenic stroma showing en-
gorgement of sinusoids by red blood cells (Figures 13,
14, 15 and 16).Figure 14 DAS-77 (80 mg/kg) group showing the spleen
(congested) (× 400).Pancreas
The pancreas was normal in all the treatment groups.
Closely packed acini, separated by delicate fibrocollagen-
ous stroma that transmits blood vessels were observed.Testes
Normal histopathological presentations were observed in
all the treatment groups. Histologic section shows sem-
iniferous tubules lined by germ cells in various stages of
development (the spermatogenic series), and containing
luminal spermatozoa. Leydig cells were seen in the
interstitium.Figure 13 Distilled water group showing the spleen (normal)
(× 400).Ovaries
Normal histopathological presentations were observed in
all the treatment groups. Histologic section of ovary
shows follicles at various stages of development as well
as corpora lutea, displayed on a fibrocellular stroma.
Mortality
Mortality recorded in the distilled water and DAS-77
(80, 400 and 2000 mg/kg) treatment groups within 30,
60 and 90 days, and the reversibility study period wereFigure 15 DAS-77 (400 mg/kg) group showing the spleen
(congested) (× 400).
Figure 16 DAS-77 (2000 mg/kg) group showing the spleen
(congested) (× 400).
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0/20 (5%); 1/20, 1/20, 0/20 and 0/20 (10%); and 1/20,
2/20, 0/20 and 1/20 (20%), respectively.
Discussion
Worldwide, various medicinal plants and botanical drugs
have been widely adapted as primary therapeutic agents
or supplements for treating various human ailments
[33]. Based on the findings that herbal medicines are
abused, there is a great need to look into their acute and
chronic toxicity effects.
DAS-77 did not induce lethality in mice when
administered orally up to 20 g/kg in divided doses.
Hence, the herbal preparation can be said to be safe
when administered orally according to the assertion
of Clarke and Clarke [34] that a substance that does
not produce lethality up to 10 g/kg orally is rela-
tively non-toxic. Visible signs of delayed toxicity
were not observed. However, the LD50 when DAS-77
was administered intraperitoneally was estimated to
be 1122.0 mg/kg. The behavioral changes observed
during acute exposures through the intraperitoneal
route were writhing, grooming, increased locomotor
activity and convulsion.
Considering the therapeutic dose of DAS-77
(400 mg/kg), the hematological analysis showed an
increase in neutrophils which possibly suggest a
boost in defense, mainly acute response to infections
or antigens. This is based on the fact that neutro-
phils are essential first line defense of the body
against infections or introduction of antigens and
neutropenia (decrease in neutrophils) makes anindividual highly susceptible to infections [35]. Other
hematological parameters were not affected. There
was an increase in the weight of the ovaries and this
could suggest preparation for ovulation cycle as the
histopathological findings showed normal presenta-
tions in the ovaries [36]. Antioxidant enzymes in the
liver and brain did not show any significant change.
However, a decrease in the level of MDA was
observed in the liver. Malondialdehyde is a non-
lipophilic peroxidation product of polyunsaturated
fatty acids containing three or more methylene inter-
rupted double bonds. Production of MDA reflects
lipid peroxidation caused by oxidative damage [37].
Food and water intake were reduced and this may
be an indicator that DAS-77 has significant effect on
the CNS based on the fact that some CNS stimu-
lants cause anorexia [38]. The herbal formulation at
the therapeutic dose did not affect sperm motility,
count and morphology. Biochemical estimations
showed an increase in HDL. Epidemiological studies
have shown that high concentrations of HDL confer
protective value against cardiovascular diseases such
as ischemic stroke and myocardial infarction. Low
concentrations of HDL increase the risk for athero-
sclerotic diseases [39]. This shows a potential for
cardioprotective effect at this dose. There was a de-
crease in the level of potassium in the serum which
suggests a potential for DAS-77 to cause electrolyte
imbalance at this dose. Potassium is essential for
many body functions, including muscle and nerve
activity. The electrochemical gradient of potassium
between the intracellular and extracellular space is
essential for nerve function. In particular, potassium
is needed to repolarize the cell membrane to a rest-
ing state after an action potential has passed.
Decreased potassium levels in the extracellular space
will cause hyperpolarization of the resting membrane
potential. The reversibility studies showed that the
effects induced by DAS-77 at the therapeutic dose in
the main study were reversed. This suggests that
these effects were not continuous after withdrawal of
administration.
In respect of the subtherapeutic dose (80 mg/kg),
DAS-77 had no significant effect on organ weights com-
pared to control. There were no significant changes in
food and water intake, and weight of animals.
Hematological findings showed increase in the percent-
age of neutrophils which possibly suggests a boost in the
immune response [35]. There was no effect on the mo-
tility, count and morphology of sperm cells. The testicu-
lar level of GSH, SOD, CAT and peroxidase were
increased with no significant effect on MDA relative to
control. The level of MDA and antioxidant enzymes in
the liver and brain were not affected. However, a
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neys. The level of MDA is a signal of lipid peroxidation
and oxidative damage and the low level observed in the
kidney shows a reduced possibility of oxidative stress
[37]. Serum electrolyte estimation showed a decrease in
potassium levels which suggest electrolyte imbalance.
This would have an effect on muscle contraction and ac-
tivities in the nervous system. Biochemical assays
showed an increase in HDL, indicating a potential for
protective value against cardiovascular diseases such as
ischemic stroke and myocardial infarction [39]. Hence,
DAS-77 at the dose of 80 mg/kg may possibly elicit car-
dioprotective effect. The effects produced by the herbal
preparation at this dose were reversed upon cessation of
administration.
DAS-77 at the supratherapeutic dose (2000 mg/kg)
also produced an increase in the size of the ovaries. This
may be due to preparation for ovulation in view of the
fact that histopathological examinations showed normal
presentation without any inflammation. There was also a
decrease in food intake which possibly suggests anorexia.
This may be an indication of impact on the CNS at this
dose. There was a decrease in the WBC count which
could be that the formulation suppresses immunity at
this dose. Differential WBC analysis revealed an increase
in the percentage of neutrophils possibly suggesting a
boost in the acute immune response of the body [35].
There was a tremendous effect on sperm motility, count
and morphology. Motility and count were significantly
reduced and the percentage of abnormal cells was high
relative to control suggesting significant reduction in
fertility. This shows that DAS-77 at this dose has a
potential for use as a male contraceptive as all the
components of a potent sperm cell were reversibly
affected. Antioxidant enzymes and MDA estimation in
the kidney showed an increase in catalase and decrease
in MDA levels which means that there is enhanced
conversion of hydrogen peroxide to water and gaseous
oxygen. Hydrogen peroxide, a free radical, is a harmful
by-product of many normal metabolic processes. To
prevent damage, it must be quickly converted into
other less dangerous substances. In view of this, cata-
lase is frequently used by cells to rapidly catalyze the
decomposition of hydrogen peroxide into less reactive
gaseous oxygen and water molecules [40]. A reduced
MDA level also shows ability to mop up dangerous
species of free radicals [37]. DAS-77 at the suprathera-
peutic dose produced a decrease in the level of potas-
sium. As stated earlier, reduction in potassium levels
in the extracellular space will cause hyperpolarization
of the resting membrane potential which may affect
activities of the nervous system. There was a signifi-
cant reduction in the levels of AST and ALT. The
levels of these enzymes are raised in acute liverdamage. AST is also present in red blood cells, cardiac
muscle, skeletal muscle, kidney and brain tissue, and
may be elevated due to damage to these sources as
well. AST is defined as a biochemical marker for the
diagnosis of acute myocardial infarction [41]. ALT is
fairly specific being found largely in the liver [8] and it
is commonly used as a biomarker for liver problems
[42]. The reduction in the levels of AST and ALT may
suggest potential for hepatoprotective action. An inde-
pendent study is however necessary to ascertain this.
The reversibility study showed that the effects pro-
duced by the herbal preparation at the supratherapeu-
tic dose in the main study were reversed.
Histopathological presentations in this study give cre-
dence to the results obtained in the assessment of
hematological and biochemical parameters with the
90 day administration of DAS-77. These findings may
suggest that the mortality recorded in the course of this
study may be administration related.
Conclusion
Findings in the acute toxicity test suggest that DAS-77 is
practically non-toxic when administered orally. The
results obtained in respect of the chronic toxicity study
suggest that DAS-77 is relatively safe when administered
orally for an extended period at subtherapeutic and
therapeutic doses. The phytomedicine at these doses
showed potential for boosting components of the im-
mune system and protecting the kidneys, liver and car-
diovascular system. These findings provide a justification
for specifically designed studies to further investigate
these possible beneficial activities. However, DAS-77 at
these doses showed a tendency to reversibly cause elec-
trolyte imbalance. Observations in this study also
revealed that the supratherapeutic dose of DAS-77 is
endowed with the potential beneficial effects observed
with the lower doses but with the risk of reversible elec-
trolyte imbalance also and additionally, reversible steril-
ity in males.
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